C. Martín y A. I. Torres
228
27.
Luo, Q.;, Gu, Y.; Zheng, W. et al. (2011) Erlotinib inhibits T-‐cell-‐mediated immune response
via down-‐regulation of the c-‐Raf/ERK cascade and Akt signaling pathway. Toxicol Appl
Pharmacol 251, 130-‐136.
28.
Duffour, J.; The´zenas, S.; Dereure, O. et al. (2010) Inter-‐observer agreement between
dermatologists and oncologists in assessing dermatological toxicities in patients with
metastatic colorectal cancer treated by cetuximab-‐based chemotherapies: A pilot
comparative study. Eur J Cancer 46, 3169-‐3174.
29.
Dinh, P.; Harnett, P.; Piccart-‐Gebhart, MJ.; Awada, A. (2008) New therapies for ovarian
cancer: Cytotoxics and molecularly targeted agents. Crit Rev Oncol/hematol; 67:103-‐112.
30.
Seiden MV, Burris HA, Matulonis U, et al. A phase II trial of EMD72000 (matuzumab), a
humanized anti-‐EGFR monoclonal antibody, in patients with platinum-‐resistant ovarian
and primary peritoneal malignancies. Gynecol Oncol 104, 727-‐731 (2007).
31.
Ismael. GF.; Dornelles. D.; Mano, MS.; Awada. A. (2008)Novel cytotoxic drugs: Old
challenges, new solutions. Cancer Treat Rev 34, 81-‐91.
32.
Hotta, K.; Ueok, H. (2005) New cytotoxic agents: a review of the literature. Crit Rev
Oncol/hematol 55, 45-‐65.
33.
Natsume, T.; Watanabe, J.; Koh, Y. et al. (2003) Antitumor activity of TZT-‐1027
(soblidotin) against vascular endothelial growth factor secreting human lung cancer in
vivo. Cancer Sci 94, 826-‐833.
34.
Natsume T, Watanabe J, Koh Y, et al. (2003) Antitumor activity of TZT-‐1027 (Soblidotin)
against vascular endothelial growth factor-‐secreting human lung cancer in vivo. Cancer
Sci 94, 826-‐ 833.
35.
Riely, GJ.; Gadgeel, S.; Rothman, I.; Saidman, B.; Sabbath, K.; Feit, K. (2007) A phase 2 study
of TZT-‐1027, administered weekly to patients with advanced non-‐small cell lung cancer
following treatment with platinum-‐based chemotherapy. Lung Cancer 55, 181-‐185.
36.
Kamsteeg, M.; Rutherford, T.; Sapi, E.; et al. (2003) Phenoxodiol –an isoflavone analog–
induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 22(17), 2611-‐2620.
37.
Aguero, MF.; Facchinetti, MM.; Sheleg, Z.; Senderowicz, AM. (2005) Phenoxodiol, a novel
isoflavone, induces G1 arrest by specific loss in cyclin-‐dependent kinase 2 activity by p53-‐
independent induction of p21WAF1/CIP1. Cancer Res 65(8), 3364-‐3373.
38.
Tonary, AM.; Macdonald, EA.; Faught, W. et al. (2000) Lack of expression of c-‐Kit in
ovarian cancers is associated with poor prognosis. Int J Cancer 89(3), 242-‐250.
39.
Reynoso, D.; Nolden, LK.; Yang, D.; et al. (2011) Synergistic induction of apoptosis by the
Bcl-‐2 inhibitor ABT-‐737 and imatinib mesylate in gastrointestinal stromal tumor cells.
Mol Oncol 5, 93-‐104.
